Back to Peptides

Kisspeptin-10

Hormone Regulation & Endocrine Support

Kisspeptin-10 is a potent regulator of reproductive hormone signaling that stimulates GnRH secretion from the hypothalamus, which in turn increases LH and FSH levels to support testosterone, estrogen, and fertility. It has been studied for its role in treating hypogonadism, improving libido, and optimizing reproductive cycles. Emerging research also suggests metabolic benefits through its effects on insulin sensitivity and fat regulation.

Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
1–10 mcg Subcutaneous (SQ)
Single dose or daily for 2–4 weeks (research setting)
Standard Dose
4 mcg
Cycle
4–8 weeks
then reassess
Kisspeptin-10GnRHreproductive health

Dosing & Reconstitution Guide

Clinical studies use doses of 0.1–1.0 μg/kg via IV or SubQ routes. These studies are investigational and not for general use.

Standard / Gradual Approach

10mg Vialstandard
PhaseDoseVolume
Weeks 1–2100 mcg3 units (0.03 mL)
Weeks 3–8 (or 3–12)200 mcg6 units (0.06 mL)

Protocol Summary

Subcutaneous (SQ): Single dose or daily for 2–4 weeks (research setting) · Dose range 1–10 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ

Inject 0.4 mcg/kg SubQ daily for 2–4 weeks, followed by reevaluation of hormonal markers. Cycle every 6–12 weeks depending on reproductive goals. Monitor for changes in LH, FSH, testosterone, or estrogen levels.

🧪 Quick Start

Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit
Starting Dose
100 mcg (3 units (0.03 mL))
Maintenance Dose
200 mcg (6 units (0.06 mL))

Potential Benefits & Use Cases

Kisspeptin-10 is a research-use-only peptide not approved for therapeutic administration.
Increases endogenous testosterone by 45% (16.6→24.0 nmol/L) by amplifying LH/FSH signals without suppressing the HPG axis (human trial)
Shows promise in restoring fertility in functional hypothalamic amenorrhea by rekindling GnRH/LH pulsatility (human trial)
Induces robust LH surge for IVF ovulation trigger with potentially lower OHSS risk vs hCG (human trial)
Stimulates testosterone production in type 2 diabetes patients with mild hypogonadism (human trial)
Enhances sperm motility and intracellular calcium dynamics (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Activates KISS1 receptors in the hypothalamus, stimulating GnRH release and increasing LH (Luteinizing Hormone) & FSH (Follicle-Stimulating Hormone) secretion.
→Enhances gonadal steroid production, leading to increased testosterone and estrogen levels.
→May improve metabolic health, influencing leptin, insulin signaling, and adipocyte function.

Lifestyle & Optimization

timing

Consistent injection schedule.

diet

Adequate nutrition and healthy body weight for endogenous hormone production.

exercise

Moderate activity as tolerated.

sleep

Sleep and stress management — HPG axis is sensitive to both. Monitor reproductive function changes.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Endocrine Reviews (Oxford Academic) — Emerging Therapeutic PotentialReference
Kisspeptin-10 Clinical Reference Sheet — Starting dose recommendationsReference
Journal of Clinical Investigation — Kisspeptin-54 triggers egg maturationReference

Side Effects & Safety

Common Side Effects

• Transient flushing (warmth and redness, face)
• Mild headache, nausea, lightheadedness

Contraindications & Warnings

• Only short-term dosing studied in humans

🧮 Dose Calculator

Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High absorption with sustained release effect.
Oral Administration
Poor bioavailability due to instability in the gastrointestinal tract.
Half-Life
Around 30 minutes in plasma.
Degradation
Rapidly degraded enzymatically in plasma.
Tissue Specificity
Primarily affects the hypothalamic-pituitary-gonadal axis.
⚗️

Peptide Details

Molecular Weight
1302.4
Formula
C63H83N17O14
Sequence
YNWNSFGLRF-NH2
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); stable up to ~4 weeks; avoid freeze–thaw